Spatial transcriptomics has also facilitated the identification of therapeutic targets enriched in specific tumor regions, including TP53, EGFR, FERMT1, CD44, S100A4, and SOX2, particularly in blood vessel‐rich and tumor‐dense areas of high‐grade gliomas (IDH wild‐type and mutant) [97]. Here, CD44 is linked to neoplasm.